Andere Sprachen Valeo Pharma Inc.

Aktien

A2PLB4

CA91915B1085

VPH

Markt geschlossen - Toronto S.E. Andere Börsenplätze 22:00:00 16.05.2024			% 5 Tage	% 1. Jan.
0,1 ^CAD	0,00 %		0,00 %	-44,44 %

25.04.	Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call
22.03.	Valeo Pharma Inc. gibt die Ernennung von Al Moghaddam zum Mitglied des Verwaltungsrats bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS	25.04.
VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE	09.04.
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS	25.03.
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS	22.03.
Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors	22.03.
VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS	14.03.
Valeo Pharma Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	14.03.
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL, WEBCAST	08.03.
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST	07.03.
VALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGES	13.02.
Valeo Pharma Inc. Announces Board Changes	13.02.
Valeo Pharma Brief: Notes Sagard credit facility amended to provide for early repayments and liquidity requirements in fiscal 2024	02.02.
Valeo Pharma Brief: Says Proceeds from reimbursement to be used for debt reduction purposes	02.02.
Valeo Pharma Brief: Adding SIMBRINZA remains under Valeo Pharma exclusive promotion and distribution	02.02.
Valeo Pharma Brief: Says Original commercialization and supply agreement amended following global divestment of XIIDRA	02.02.
Valeo Pharma Brief: Amending Agreement With Novartis Pharmaceuticals Canada For XIIDRA In Canada, and Credit Facility With Sagard Healthcare Royalty Partners, LP	02.02.
VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP	02.02.
Valeo Pharma Amends Agreement with Novartis Pharmaceuticals Canada for (Pr)XIIDRA in Canada	02.02.
Valeo Pharma Inc. Amends Credit Facility with Sagard Healthcare Partners, LP	02.02.
Valeo Pharma's Q4'23 Net Loss Holds Steady YOY	30.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Valeo Pharma Inc.

Aktien

A2PLB4

CA91915B1085

VPH

Andere Sprachen

Filter